![5000100-flag[1].jpg](https://cdn.european-virus-archive.com/cdn/farfuture/BIcd6Z7a1Uzb5LahErSGdoyqhDpItm5zvumsM9sBY60/mtime:1484756601/sites/default/files/5000100-flag%5B1%5D.jpg)
The best way to get viral material within the Scientific Community. Browse our viruses and derived products from the EVAg Portal.
A unique biological resource in the field of virology, readily available online. Users may benefit from special funding to access to products of interest, do not hesitate to apply.
An international group of 25 laboratories, including 16 EU member state institutions and 9 non-EU institutions, that represent an extensive range of virological disciplines.
An open entity aiming at developing synergies and complementary capabilities in such a way as to offer an improved access to researchers.
The quality of viruses and derived products is a key consideration when our products are to be made available. Improvements on quality process will be addressed during the project.
EVAg generates and distributes globally diagnostic materials and protocols in the event of epidemiological emergencies.
Focused on the creation of new tools, techniques and concepts to develop the infrastructure and to provide easier and less expensive access to virological materials.
A user-friendly web Portal with a continuously increasing number of viruses and derived products. Start here...
The EVAg initiative will increase competitiveness and, provides for a strong interaction with industry and a promising foundation for the innovation process between academia and industry.
- The European Commission -
The initiative has an important social impact with particular emphasis on human disease.
- The European Commission -
The quality of the installations cooperating in this consortium is excellent, representing some of the best available infrastructures across the EU and world-wide.
- The European Commission -
EVAg is a proud partner of the ECRAID network ! #kickingoffECRAID 17 Jan 2019: stay tuned https://t.co/4ENYjwfMUz
Message for the #WVCEU attendants: enjoy your lunch break and come talk to us at booth 6! We're a #H2020 funded biobank distributing viral strains (human and animal) and derived products. Our Business Developer is here to answer your questions. https://t.co/zDif1qNOiM
After an unplanned landing in Faro due to a radar problem in Lisboa airport, our team finally made it to Lisboa thus renouncing to beautiful beaches and surf of South Portugal... Great dedication, motivated by #WVCEU splendid program ! Visit our booth ! https://t.co/3aAwNu1U54
World Vaccine Congress Europe just started in Lisboa. Interesting discussion about challenges in translating research into vaccine products. Can we continue to be dependent on industry for process development... #WVCEU
Last @EVAg_EU #H2020 general assembly had a different format: workshops, small group discussions, brainstorming sessions... busy times ! Big Thank You to the University of Ljubljana team for hosting us, including amazing Slovenian food and wine tasting ;) https://t.co/67pJ4orjY1
Congrats :) ! https://t.co/cQlQi7RlGA
Well, given the recent news concerning arboviruses in Europe, this new training on serological detection of arboviruses from our partner comes at a perfect timing... @ErasmusMC @MarionKoopmans Limited space available, free of charge from our portal. https://t.co/1oFyH0UGBq https://t.co/He3KV1fzRM
Coudn't agree more ! https://t.co/Og8MF0ZyV9
A one-day workshop was organised by our EVAg partner Animal and Plant Health Agency, APHA on the 15th of October, 2016. The aim of this workshop was t... read more
The next American Society of Tropical Medicine and Hygiene Annual Meeting will be held in November 13-17, 2016, in Atlanta, Georgia, USA.... read more
The World Health Organisation (WHO) has warned that Zika virus (ZIKV), a mosquito-borne virus that can infect humans, is likely to spread across the ... read more
We at Luminex were sincerely appreciative of your willingness to work with us during the development of our xMAP® MultiFLEX™ Zika RNA Assay. The materials from EVAg supported our FDA submission, which is now authorized for emergency use.
Sarah M. Dunlap, PhDDirector, Clinical Operations - Luminex Corporation
We received high quality products at no cost. It helped us a lot in achieving our project. Thank you!
John UserR & D - Laboratory
